Technology ID
TAB-2650

Method of Enhancing Opsonophagocytosis

E-Numbers
E-329-2013-0
E-338-2013-0
Lead Inventor
Ades, Edwin (CDC)
Co-Inventors
Rajam, GowriSankar (CDC)
Steiner, Sandra (CDC)
Carlone, George (CDC)
Atwell-Melnick
Melnick, Nikkol (CDC)
Sampson, Jacquelyn (CDC)
Martinez, Joseph (CDC)
Caba, Joseph (CDC)
Applications
Vaccines­­­
Therapeutics
Diagnostics
Therapeutic Areas
Infectious Disease
Development Status
  • Pre-clinical
  • In vitro data available
  • In vivo data available (animal)
Lead IC
CDC
ICs
CDC
This invention aims to bolster the human body's own mechanisms to fight infection by enhancing an innate immune response, opsonophagocytosis. The specific 24 amino acid sequence (P4) acts as a polymorphonuclear cell activator. P4 can be administered in vivo along with a disease's specific antibody to enhance systemic bacterial clearance, thus leading to prolonged survival. This technology enhances the body's response to infections such as S. pneumoniae and S. aureus.
Commercial Applications
  • Opsonic therapy
  • Passive immunization
  • Enhancement of pathogen clearing
  • Synergistic use with other therapies
Competitive Advantages
  • Multiple in vivo studies indicate significant improvements in recipient outcomes
  • Highly adaptable and can be combined with a number of alternate therapies
  • Enhances opsonophagoctyosis to achieve therapeutically effective results

Request More Info

Licensing Contact:
Motley, Jonathan
jonathan.motley@nih.gov

Patents

  • US
    Provisional (PRV) 60/682,495
    Filed on 2005-05-19
  • Patent Cooperation Treaty
    (PCT) PCT/US2009/052384
    Filed on 2009-07-31
  • US
    Provisional (PRV) 61/085,208
    Filed on 2008-07-31
  • US Patent 8,431,134
    Filed on 2011-01-28
  • US Patent 9,101,582
    Filed on 2013-03-27
  • Patent Cooperation Treaty
    (PCT) PCT/US2005/027290
    Filed on 2005-07-29
  • US Patent 7,919,104
    Filed on 2008-07-18

Publications

Collaborations

  • Licensing
  • Collaboration

Collaboration Description

  • The Centers for Disease Control and Prevention (CDC) is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize Methods and Tools for Enhancing Opsonophagocytosis in Response to a Pathogen. For collaboration opportunities, please contact Suzanne Shope at sshope@cdc.gov or 770-488-8613.
Date Published